Phillip Helding, DO
Addiction Medicine · Hinsdale, ILNPI 1043351026
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.8% of the total across 406 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Among addiction medicine clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 406 payments — averaging $19.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Supernus Pharmaceuticals, Inc.$1K
- Neurocrine Biosciences, Inc.$836
- Teva Pharmaceuticals USA, Inc.$702
- Johnson & Johnson$662
- Otsuka America Pharmaceutical, Inc.$494
- plus $3K from 20 others
What the payments were for
- Food & beverage$7,70396%
- Education$3414%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 74 | $1,419 |
| Supernus Pharmaceuticals, Inc. | 72 | $1,034 |
| Neurocrine Biosciences, Inc. | 27 | $836 |
| Teva Pharmaceuticals USA, Inc. | 23 | $702 |
| Johnson & Johnson | 30 | $662 |
| Otsuka America Pharmaceutical, Inc. | 24 | $494 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $396 |
| Ironshore Pharmaceuticals Inc. | 18 | $329 |
| Corium, LLC | 17 | $316 |
| Alkermes, Inc. | 14 | $292 |
| Tris Pharma Inc | 15 | $274 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $227 |
| Almatica Pharma LLC | 11 | $159 |
| Neos Therapeutics, LP | 10 | $158 |
| Sunovion Pharmaceuticals Inc. | 7 | $121 |
| Adlon Therapeutics L.p. | 7 | $121 |
| E.r. Squibb & Sons, L.L.C. | 4 | $115 |
| Noven Therapeutics, LLC | 6 | $90 |
| Shire North American Group Inc | 4 | $77 |
| Axsome Therapeutics, Inc. | 3 | $62 |
| Xeris Pharmaceuticals, Inc. | 2 | $39 |
| Jazz Pharmaceuticals Inc. | 2 | $39 |
| Alfasigma USA, Inc. | 2 | $31 |
| Indivior Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Tempus AI, Inc | 1 | $15 |
How this compares
$8,044 in reported general payments places this provider in the 90th percentile of 47 addiction medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 23 | $176,093 |
| VyvanseLisdexamfetamine Dimesylate | 41 | $20,079 |
| Lisdexamfetamine Dimesylate | 47 | $11,355 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 217 | $8,976 |
| Aripiprazole | 140 | $6,948 |
| Ziprasidone Hcl | 55 | $5,737 |
| Adderall XrDextroamphetamine/Amphetamine | 24 | $5,115 |
| Bupropion XlBupropion Hcl | 349 | $4,959 |
| Quetiapine Fumarate | 236 | $4,055 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 25 | $4,043 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 75 | $4,032 |
| Trazodone Hcl | 231 | $2,910 |
| Atomoxetine Hcl | 24 | $2,777 |
| Alprazolam | 367 | $2,668 |
| Duloxetine Hcl | 126 | $2,329 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $836 | $176,09323 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $396 | $20,07941 claims |
| Almatica Pharma LLCSertraline Hcl | $159 | $1,340185 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 47 addiction medicine providers in Illinois.
Other addiction medicine in Hinsdale
- Roueen RafeyanChicago$2.4M
- Abhinav SinglaJoliet$115K
- Leonard SpishakoffRomeoville$11K
- Adeyemi FatokiOttawa$8K
- Michael BlainEldorado$6K
- Albert TanlimWatseka$5K
- Francesco TaniChicago$4K
- Neha DattaOrland Park$4K
- Paul BonucciPrinceton$3K
- Risha FennellNormal$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.